abrdn Healthcare Opportunities Fund declares $0.18 dividend
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 12 2025
0mins
Source: SeekingAlpha
Dividend Declaration: abrdn Healthcare Opportunities Fund (THQ) announced a monthly dividend of $0.18 per share, consistent with previous payments, payable on March 31 to shareholders of record by March 25.
Market Insights: Despite improved performance, THQ is trading at fair value amid healthcare sector weaknesses, suggesting potential opportunities but also indicating that better alternatives may exist.
Analyst Views on THQ
Wall Street analysts forecast THQ stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for THQ is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 19.790
Low
Averages
High
Current: 19.790
Low
Averages
High
No data
About THQ
abrdn Healthcare Opportunities Fund (the Fund), formerly Tekla Healthcare Opportunities Fund, is a non-diversified closed-end management investment company. The Fund's investment objective is to seek current income and long-term capital appreciation through investments in United States and non-United States companies in the healthcare industry, including equity securities, debt securities and pooled investment vehicles. It invests primarily in securities of public and private companies. The Fund invests up to 20 % of managed assets, measured at the time of investment, in the debt of healthcare companies. The Fund also invests in private companies and other restricted securities, including private investments in public equity and venture capital investments. It invests in health care providers and services, pharmaceuticals, health care equipment and supplies, life sciences tools and services, biotechnology, and medical devices and diagnostics. The Fund's investment adviser is abrdn Inc.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
